Aerovate Therapeutics【AVTE】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

2.07

買値

1.99

売値

2.13

出来高

0.00 日の範囲 0.00

1.25 52 週間の範囲 32.415

時価総額

59.756M

前日終値

2.07

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

289,825

発行済株式数

28,867,711

配当利回り

PER

-0.79

1 株当たり利益 (EPS)

-2.62

歳入

純利益

-75.52M

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hyper... Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.aerovatetx.com

本社

Wilmington, Delaware, USA

設立

Aerovate Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker AVTE. The last closing price for Aerovate Therapeutics was US$2.07. Over the last year, Aerovate Therapeutics shares have traded in a share price range of US$ 1.25 to US$ 32.415.

Aerovate Therapeutics currently has 28,867,711 shares in issue. The market capitalisation of Aerovate Therapeutics is US$59.76 million. Aerovate Therapeutics has a price to earnings ratio (PE ratio) of -0.79.

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

WALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.09	4.54545454545	1.98	2.13	1.9231	117593	2.07293707	CS
4	0.2	10.6951871658	1.87	2.13	1.84	215147	1.94192967	CS
12	0.27	15	1.8	2.13	1.61	289825	1.86686691	CS
26	-26.93	-92.8620689655	29	30.29	1.25	661842	4.20985299	CS
52	-11.12	-84.3062926459	13.19	32.415	1.25	383668	6.33199619	CS
156	-18.45	-89.9122807018	20.52	32.415	1.25	188005	10.04676735	CS
260	-25.93	-92.6071428571	28	32.415	1.25	183556	10.50681912	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
ELABElevai Labs Inc	US$ 0.1378 (61.74%)	116.74M
PEGYPineapple Energy Inc	US$ 0.1639 (42.65%)	89.89M
RZLVRezolve AI Ltd	US$ 9.50 (39.30%)	303.13k
INVInnventure Inc	20.50 (36.58%)	31.22k
MLGOMicroAlgo Inc	US$ 0.3822 (23.29%)	33.93M
KXINKaixin Holdings	US$ 0.2671 (-21.92%)	8.5M
ANIPANI Pharmaceuticals Inc	US$ 46.12 (-19.79%)	25
SNGXSoligenix Inc	US$ 3.97 (-18.48%)	122.51k
HOLOMicroCloud Hologram Inc	US$ 0.2811 (-18.28%)	5.65M
DUOFangDD Network Group Ltd	US$ 3.58 (-18.26%)	1.98M
ELABElevai Labs Inc	US$ 0.1378 (61.74%)	116.74M
PEGYPineapple Energy Inc	US$ 0.1639 (42.65%)	89.89M
MLGOMicroAlgo Inc	US$ 0.3822 (23.29%)	33.93M
CDTConduit Pharmaceuticals Inc	US$ 0.108 (13.68%)	25.7M
KXINKaixin Holdings	US$ 0.2671 (-21.92%)	8.5M